ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin

Anticancer Research

Volumn 22, Issue 4, 2002, Pages 1993-1999

  Smith, Vicki ^a   Hobbs, Stephen ^a   Court, William ^a   Eccles, Suzanne ^a   Workman, Paul ^a   Kelland, Lloyd R ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Chemosensitivity; Cisplatin; ErbB2; Geldanamycin; Ovarian cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 4 (3 BROMOANILINO) 6,7 DIMETHOXYQUINAZOLINE; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR; EMODIN; FLAVOPIRIDOL; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; RADICICOL; TIPIFARNIB; UO 126;

ARTICLE; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN FUNCTION; SURVIVAL;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; BENZOQUINONES; CHROMONES; CISPLATIN; EMODIN; ENZYME INHIBITORS; FEMALE; GENES, ERBB-2; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MORPHOLINES; QUINONES; RECEPTOR, ERBB-2; TUMOR CELLS, CULTURED;

EID: 0036339108     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
2. Neu and its ligands: From an oncogene to neural factors
3. Dominant negative inhibition of the association between beta-catenin and c-erbB-2 by N-terminally deleted beta-catenin suppresses the invasion and metastasis of cancer cells
4. c-erbB-2/neu ovrexpression enhances metastatic potential of human lung cancer cells by induction of metastasis-associated properties
5. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
6. ERBB 2 oncogene in human breast cancer and its clinical significance
7. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
8. Dual effect of erbB-2 depletion on the regulation of DNA repair and cell cycle mechanisms in non-small cell lung cancer cells
9. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer
10. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells
11. Effects of c-erbB2 overexpression on the drug sensitivities of normal human mammary epithelial cells
12. Human ovarian-carcinoma cell lines and companion xenografts: A disease-oriented approach to new platinum anticancer drug discovery
13. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro
14. Identification of a novel inhibitor of mitogen-activated protein kinase kinase
15. PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner
16. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin
17. Depletion of the erbB-2 gene product p185 by benzoquinoid ansamycins
18. The benzoquinone ansamycin 17-allylamino-17-denethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
19. Phase I trial of the heat shock protein 90 (HSP90) inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG). Pharmacokinetic (PK) profile and pharmacodynamic (PD) endpoints
20. Phase I trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG) in patients (pts) with advanced solid malignancies
21. Phase I pharmacologic study of 17-(allyamino)-17-demethoxygeldanamycin (AAG) in adult patients with advanced solid tumors
22. Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol
23. A phase II trial flavopiridol in patients with stage IV non-small cell lung cancer
24. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma
25. Hui KY adn Brown RF A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholiny)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
26. Biological properties of ten human ovarian carcinoma cell lines: Calibration in vitro against four platinum complexes
27. Development of a bicistronic vector driven by the human polypeptide chain elongation factor lalpha promoter for creation of stable mammalian cell lines that express very high levels of recombinant proteins
28. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
29. Rat MAbs to the product of the c-erbB-2 proto-oncogene for diagnosis and therapy in breast cancer
30. Tyrosine phosphatase inhibition permits analysis of signal transduction complexes in p185HER2/neu-overexpressing human tumor cells
31. Involvement of the c-erbB-2 oncogene product in the EGF-induced cell motility of SK-OV-3 ovarian cancer cells
32. Biochemical and clinical implications of the erb/Her signaling network of growth factor receptros
33. Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
34. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
35. Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185 (erbB-2) is dependent on the ras signaling pathway
36. Overexpression of ErbB2 blocks taxol-induced apoptosis by upregulation of p21 (Cip1), which inhibits p34 (Cdc2) kinase
37. Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the HSP90 molecular chaperone
38. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells
39. Specificity and mechanism of action of some commonly used protein kinase inhibitors
40. Induction of apoptosis and inhibition of c-erbB-2 in breast cancer cells by flavopiridol